Can a standardized MRI accurately stage esophageal cancer?
NCT ID NCT07769658
First seen Aug 18, 2026 · Last updated Aug 19, 2026 · Updated 1 time
Summary
This trial aims to develop and validate a standardized MRI protocol for staging esophageal squamous cell carcinoma and assessing how well tumors respond to neoadjuvant therapy. About 500 adults scheduled for surgery will be enrolled, with some undergoing MRI before surgery and others before and after treatment. The MRI results will be compared with the actual tumor pathology to see if the imaging can reliably determine the extent of the cancer and the degree of regression after therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Standardized 3.0-T esophageal magnetic resonance imaging (MRI) protocol
- What this could lead to
- If successful, this could establish a reliable, non-invasive imaging standard for staging esophageal cancer and evaluating treatment response, potentially reducing the need for invasive procedures.
- What could go wrong
- The trial is diagnostic and exploratory, with accuracy dependent on image quality and reader expertise. MRI may not perfectly match pathological findings, and results may vary across centers and equipment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 500 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Sep 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adults aged 18-80 years with histologically confirmed thoracic esophageal squamous cell carcinoma who are scheduled for curative esophagectomy at seven tertiary hospitals in China. Eligible patients will be enrolled consecutively. Cohort membership is determined by the clinical treatment pathway (upfront surgery or neoadjuvant therapy followed by surgery) selected by the treating multidisciplinary team independently of study participation. MRI examinations are performed as part of routine clinical care.
- Ages
-
18 to 80 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 to 80 years, inclusive * Histologically confirmed esophageal squamous cell carcinoma based on endoscopic biopsy or other tissue examination * Primary tumor located in the thoracic esophagus * Planned curative esophagectomy * Able to complete the required esophageal MRI examination with diagnostically adequate image quality * Able and willing to provide written informed consent * For Cohort A: no chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other antitumor treatment before MRI; surgery planned within 14 days after MRI; and postoperative pathological T stage expected to be available * For Cohort B: neoadjuvant treatment followed by surgery selected by the clinical multidisciplinary team; baseline MRI completed within 14 days before neoadjuvant treatment; post-treatment MRI completed within 14 days before surgery; and pathological tumor regression grade of the primary tumor bed expected to be available Exclusion Criteria: * Adenocarcinoma, neuroendocrine carcinoma, adenosquamous carcinoma, or another non-squamous histological type * Cervical esophageal cancer, a gastric primary tumor extending into the esophagus, or multiple primary lesions that prevent reliable imaging-pathology matching * Definite distant metastasis, unresectable T4b disease, or another reason that prevents acquisition of a surgical pathological reference standard * Previous esophageal cancer surgery, radiotherapy, or another treatment that substantially altered local esophageal anatomy * Contraindication to MRI, or contraindication to the gadolinium-based contrast agent when the required contrast-enhanced sequences cannot be completed * Severe claustrophobia, inability to follow breathing instructions, or another cause of nondiagnostic image quality that persists after a safe repeat examination * Substantial disease progression, emergency intervention, or off-protocol treatment between MRI and surgery that prevents valid imaging-pathology comparison * Inadequate surgical specimen sampling or inability to determine pathological T stage or pathological tumor regression grade
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Esophageal squamous cell carcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
7 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
-
Henan Provincial Chest Hospital (Zhengzhou University Affiliated Chest Hospital)
Zhengzhou, Henan, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Yunnan Cancer Hospital
Kunming, Yunnan, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Experimental drug put to the test against Hard-to-Treat GI cancers
- Can a drug combo shrink esophageal tumors before surgery?
- Two-Drug combo targets esophageal cancer that outsmarted immunotherapy
- Can a Triple-Drug combo shrink esophageal tumors before surgery?
- Can a Triple-Drug combo wipe out esophageal tumors before surgery?
- Dye-Guided surgery may spare healthy lymph nodes in esophageal cancer